Comments
Loading...

BioXcel Therapeutics

BTAINASDAQ
Logo brought to you by Benzinga Data
$0.700000
0.046.67%
Pre-Market: 7:36 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$1.00
Consensus Price Target1
$7.43

BioXcel Therapeutics (NASDAQ:BTAI) Stock, Analyst Ratings, Price Targets, Forecasts

BioXcel Therapeutics Inc has a consensus price target of $7.43 based on the ratings of 9 analysts. The high is $22 issued by Jefferies on March 10, 2023. The low is $1 issued by UBS on August 9, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and UBS on September 6, 2024, August 30, 2024, and August 9, 2024, respectively. With an average price target of $5 between HC Wainwright & Co., Canaccord Genuity, and UBS, there's an implied 614.29% upside for BioXcel Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
1
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Canaccord Genuity
UBS
B of A Securities
Mizuho

1calculated from analyst ratings

Analyst Ratings for BioXcel Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for BioXcel Therapeutics (BTAI) stock?

A

The latest price target for BioXcel Therapeutics (NASDAQ:BTAI) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $7.00 expecting BTAI to rise to within 12 months (a possible 900.00% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?

A

The latest analyst rating for BioXcel Therapeutics (NASDAQ:BTAI) was provided by HC Wainwright & Co., and BioXcel Therapeutics reiterated their buy rating.

Q

When was the last upgrade for BioXcel Therapeutics (BTAI)?

A

The last upgrade for BioXcel Therapeutics Inc happened on December 1, 2022 when Goldman Sachs raised their price target to $16. Goldman Sachs previously had a sell for BioXcel Therapeutics Inc.

Q

When was the last downgrade for BioXcel Therapeutics (BTAI)?

A

The last downgrade for BioXcel Therapeutics Inc happened on February 21, 2024 when UBS changed their price target from $9 to $4 for BioXcel Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

Q

Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?

A

While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a reiterated with a price target of $7.00 to $7.00. The current price BioXcel Therapeutics (BTAI) is trading at is $0.70, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch